News

Home>News
News2020-07-17T11:41:26-04:00
Sep 212020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

September 21st, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , , |

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers.  Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will immediately commence the identification of suitable antibodies. Dr. Chen expects to have proprietary antibodies within the next two weeks. Patent ...

Sep 172020

Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

September 17th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent antibody-antigen complex, for the rapid identification of a Covid-19 sample. In an earlier press release, we enumerated the initial phase ...

Sep 142020

Halberd Corporation Outlines Multi-Phase $1.4 M Covid-19 Program in Partnership With ASU

September 14th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based upon the following two provisional patent applications: Method for Treating and Curing Covid-19 Infection, and Method for the Rapid Identification ...

Sep 82020

Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU

September 8th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood.  Those antibodies could be multifaceted, including with regard to other viruses. The research ...

Sep 22020

Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

September 2nd, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services funding among all U.S. institutions without a medical school, placing them ahead of Princeton, Georgia Tech and Carnegie Mellon University.  ...

Go to Top